Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-019730

CHIEF FINANCIAL OFFICER sold 1,000 shares at $22.66 ($22,655)

  • CHIEF FINANCIAL OFFICER acquired 1,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2025-07-10 Option exercise 10b5-1 +1,000 $2.48 $2,480 24,000 D: show line 1 in the form
Hohl Benjamin CHIEF FINANCIAL OFFICER 2025-07-10 Sale 10b5-1 −1,000 $22.66 $22,655 23,000 D: show line 2 in the form
Open-market sales · 1,000 sh · avg $22.66 · $22,655

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2025-07-10 Option exercise · Stock Option (right to buy) 10b5-1 −1,000 114,806 D: show line 3 in the form
Loading xslF345X05/form4-07142025_090730.xml…